JP2020125323A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020125323A5 JP2020125323A5 JP2020073065A JP2020073065A JP2020125323A5 JP 2020125323 A5 JP2020125323 A5 JP 2020125323A5 JP 2020073065 A JP2020073065 A JP 2020073065A JP 2020073065 A JP2020073065 A JP 2020073065A JP 2020125323 A5 JP2020125323 A5 JP 2020125323A5
- Authority
- JP
- Japan
- Prior art keywords
- viral
- coat protein
- protein
- viral coat
- protein complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000565 Capsid Proteins Proteins 0.000 claims 44
- 108010067390 Viral Proteins Proteins 0.000 claims 30
- 241001465754 Metazoa Species 0.000 claims 24
- 238000000034 method Methods 0.000 claims 22
- 230000003472 neutralizing effect Effects 0.000 claims 20
- 238000004519 manufacturing process Methods 0.000 claims 16
- OQALFHMKVSJFRR-UHFFFAOYSA-N dityrosine Chemical compound OC(=O)C(N)CC1=CC=C(O)C(C=2C(=CC=C(CC(N)C(O)=O)C=2)O)=C1 OQALFHMKVSJFRR-UHFFFAOYSA-N 0.000 claims 14
- 108090000623 proteins and genes Proteins 0.000 claims 12
- 102000004169 proteins and genes Human genes 0.000 claims 11
- 230000003612 virological effect Effects 0.000 claims 11
- 230000001681 protective effect Effects 0.000 claims 10
- 230000005875 antibody response Effects 0.000 claims 8
- 230000002163 immunogen Effects 0.000 claims 6
- 108091008875 B cell receptors Proteins 0.000 claims 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 4
- 241000711513 Mononegavirales Species 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 4
- 229960005486 vaccine Drugs 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 3
- 238000004132 cross linking Methods 0.000 claims 3
- 241000711573 Coronaviridae Species 0.000 claims 2
- 241000710831 Flavivirus Species 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- 241000709664 Picornaviridae Species 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- 241001529453 unidentified herpesvirus Species 0.000 claims 2
- 241000712461 unidentified influenza virus Species 0.000 claims 2
- 241001430294 unidentified retrovirus Species 0.000 claims 2
- 101710132601 Capsid protein Proteins 0.000 claims 1
- 101710094648 Coat protein Proteins 0.000 claims 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims 1
- 101710125418 Major capsid protein Proteins 0.000 claims 1
- 102000007474 Multiprotein Complexes Human genes 0.000 claims 1
- 101710141454 Nucleoprotein Proteins 0.000 claims 1
- 101710083689 Probable capsid protein Proteins 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022128985A JP7472209B2 (ja) | 2012-05-09 | 2022-08-12 | 立体構造的に特異的なウイルス免疫原 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644830P | 2012-05-09 | 2012-05-09 | |
| US61/644,830 | 2012-05-09 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018088600A Division JP6692853B2 (ja) | 2012-05-09 | 2018-05-02 | 立体構造的に特異的なウイルス免疫原 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022128985A Division JP7472209B2 (ja) | 2012-05-09 | 2022-08-12 | 立体構造的に特異的なウイルス免疫原 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020125323A JP2020125323A (ja) | 2020-08-20 |
| JP2020125323A5 true JP2020125323A5 (https=) | 2021-05-20 |
Family
ID=49548782
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015511675A Pending JP2015518819A (ja) | 2012-05-09 | 2013-05-09 | 立体構造的に特異的なウイルス免疫原 |
| JP2018088600A Expired - Fee Related JP6692853B2 (ja) | 2012-05-09 | 2018-05-02 | 立体構造的に特異的なウイルス免疫原 |
| JP2020073065A Pending JP2020125323A (ja) | 2012-05-09 | 2020-04-15 | 立体構造的に特異的なウイルス免疫原 |
| JP2022128985A Active JP7472209B2 (ja) | 2012-05-09 | 2022-08-12 | 立体構造的に特異的なウイルス免疫原 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015511675A Pending JP2015518819A (ja) | 2012-05-09 | 2013-05-09 | 立体構造的に特異的なウイルス免疫原 |
| JP2018088600A Expired - Fee Related JP6692853B2 (ja) | 2012-05-09 | 2018-05-02 | 立体構造的に特異的なウイルス免疫原 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022128985A Active JP7472209B2 (ja) | 2012-05-09 | 2022-08-12 | 立体構造的に特異的なウイルス免疫原 |
Country Status (7)
| Country | Link |
|---|---|
| US (6) | US20130302366A1 (https=) |
| EP (2) | EP3483174A1 (https=) |
| JP (4) | JP2015518819A (https=) |
| AU (5) | AU2013259548A1 (https=) |
| CA (1) | CA2873048C (https=) |
| IN (1) | IN2014DN09445A (https=) |
| WO (1) | WO2013169961A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10125172B2 (en) | 2013-07-25 | 2018-11-13 | Calder Biosciences Inc. | Conformationally stabilized RSV pre-fusion F proteins |
| ES2832733T3 (es) | 2013-08-03 | 2021-06-11 | Calder Biosciences Inc | Métodos de preparación y uso de complejos de hemaglutinina del virus de la gripe |
| CN119529036A (zh) | 2017-08-07 | 2025-02-28 | 考尔德生物科技有限公司 | 构象稳定的rsv预融合f蛋白 |
| US11623004B2 (en) | 2018-03-16 | 2023-04-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Compositions and methods for vaccination against respiratory syncytial virus infection |
| AU2021271016A1 (en) * | 2020-05-12 | 2023-01-19 | The Regents Of The University Of California | SARS-CoV2 neutralizing single domain antibody constructs |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7311920B1 (en) * | 1999-10-08 | 2007-12-25 | University Of Maryland Biotechnology Institute | Virus coat protein/receptor chimeras and methods of use |
| PT1221968E (pt) * | 1999-10-13 | 2010-04-16 | Novartis Vaccines & Diagnostic | Processo de obtenção de respostas imunes celulares de proteínas |
| WO2001029247A1 (en) * | 1999-10-15 | 2001-04-26 | Avatar Medical, Llc | Stabilized proteins |
| US6465425B1 (en) | 2000-02-10 | 2002-10-15 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins |
| US7179468B1 (en) * | 2000-06-08 | 2007-02-20 | Cornell Research Foundation, Inc. | Antigen for developing neutralizing antibodies to human immunodeficiency virus |
| EP1463521A4 (en) | 2001-12-17 | 2009-06-24 | Us Gov Health & Human Serv | INHIBITOR OF GP41 |
| US20080206264A1 (en) | 2003-02-04 | 2008-08-28 | New York University | Constrained Hiv V3 Loop Peptides as Novel Immunogens and Receptor Antagonists |
| ATE532793T1 (de) * | 2003-07-03 | 2011-11-15 | Avatar Biotechnologies Inc | Verfahren zur herstellung von molekülen mit verminderter immunogenität |
| JP5069558B2 (ja) * | 2004-06-01 | 2012-11-07 | メルク・シャープ・エンド・ドーム・コーポレイション | ＨＩＶｇｐ４１融合中間物質の安定したペプチド模倣薬 |
| EP2040747A4 (en) * | 2006-06-19 | 2010-08-25 | Progenics Pharm Inc | SOLUBLE STABILIZED TRIMERS HIV CREAM PROTEINS AND ITS USE |
| CN103864893B (zh) * | 2007-07-27 | 2017-01-04 | 伊玛提克斯生物技术有限公司 | 免疫疗法的免疫抗原表位 |
| JP2010536341A (ja) | 2007-08-15 | 2010-12-02 | アムニクス， インコーポレイテッド | 生物学的に活性なポリペプチドの特性を改変するための組成物および方法 |
| US20090246191A1 (en) * | 2007-10-11 | 2009-10-01 | University Of Tennessee Research Foundation | Preparation of Purified Covalently Cross-linked Abeta Oligomers and Uses Thereof |
| SMT202000101T1 (it) * | 2008-10-10 | 2020-03-13 | Childrens Medical Center | Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente |
| US20110123556A1 (en) | 2009-11-24 | 2011-05-26 | Sanjay Phogat | Immunogen prioritization for vaccine design |
| EP2572196A4 (en) | 2010-05-18 | 2014-04-23 | Christopher P Marshall | ASSAY TO IDENTIFY ANTIGENES FOR THE ACTIVATION OF B-CELL RECEPTORS WITH NEUTRALIZING ANTIBODIES |
| WO2013063366A2 (en) * | 2011-10-27 | 2013-05-02 | Stc.Unm | Methods for screening viral like particles and identifying neutralizing epitopes and related vaccines, constructs, and libraries |
| WO2013107290A1 (en) | 2012-01-20 | 2013-07-25 | The Government of the Hong Kong Special Administrative Region of the People's Republic of China | A novel paramyxovirus and uses thereof |
-
2013
- 2013-05-08 US US13/890,226 patent/US20130302366A1/en not_active Abandoned
- 2013-05-09 IN IN9445DEN2014 patent/IN2014DN09445A/en unknown
- 2013-05-09 CA CA2873048A patent/CA2873048C/en active Active
- 2013-05-09 AU AU2013259548A patent/AU2013259548A1/en not_active Abandoned
- 2013-05-09 EP EP18200812.8A patent/EP3483174A1/en active Pending
- 2013-05-09 EP EP13787969.8A patent/EP2846828B1/en not_active Not-in-force
- 2013-05-09 WO PCT/US2013/040228 patent/WO2013169961A1/en not_active Ceased
- 2013-05-09 US US13/890,465 patent/US20130317205A1/en not_active Abandoned
- 2013-05-09 JP JP2015511675A patent/JP2015518819A/ja active Pending
-
2017
- 2017-02-03 US US15/424,107 patent/US10155023B2/en active Active
-
2018
- 2018-01-22 AU AU2018200502A patent/AU2018200502B2/en not_active Ceased
- 2018-05-02 JP JP2018088600A patent/JP6692853B2/ja not_active Expired - Fee Related
- 2018-12-08 US US16/214,074 patent/US20190105368A1/en not_active Abandoned
-
2019
- 2019-08-16 AU AU2019216695A patent/AU2019216695A1/en not_active Abandoned
-
2020
- 2020-04-15 JP JP2020073065A patent/JP2020125323A/ja active Pending
- 2020-11-30 US US17/107,067 patent/US11752191B2/en active Active
-
2021
- 2021-06-21 AU AU2021204169A patent/AU2021204169B2/en active Active
-
2022
- 2022-08-12 JP JP2022128985A patent/JP7472209B2/ja active Active
-
2023
- 2023-08-25 US US18/455,787 patent/US20240238369A1/en not_active Abandoned
-
2024
- 2024-02-22 AU AU2024201200A patent/AU2024201200A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020125323A5 (https=) | ||
| Schirmbeck et al. | Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: implication for the pathogenesis of HBV-induced hepatitis | |
| JPH05500517A (ja) | 後天性免疫不全症候群の予防および治療 | |
| JP2002537355A (ja) | 抗原の粘膜送達のための生体接着剤およびアジュバントの使用 | |
| WO2013185558A1 (zh) | 用于治疗hbv感染及相关疾病的多肽及抗体 | |
| Koletzki et al. | HBV core particles allow the insertion and surface exposure of the entire potentially protective region of Puumala hantavirus nucleocapsid protein | |
| CN115850506B (zh) | 一种cd4辅助性t细胞表位融合肽及其疫苗 | |
| Lazo et al. | A recombinant SARS-CoV-2 receptor-binding domain expressed in an engineered fungal strain of Thermothelomyces heterothallica induces a functional immune response in mice | |
| JP2015518819A5 (https=) | ||
| TW201733616A (zh) | 包含固定化病毒粒子之疫苗 | |
| GB2294047A (en) | Synthetic peptides for use as epitopes specific for HIV | |
| Deng et al. | A novel strategy for an anti-idiotype vaccine: nanobody mimicking neutralization epitope of porcine circovirus type 2 | |
| JPH0195773A (ja) | エイズの診断、予防、又は治療に有用な新規なｈｉｖ蛋白質及びペプチド類 | |
| JP2018533908A5 (https=) | ||
| JP2007504112A5 (https=) | ||
| Khawaja et al. | Enhanced magnitude and breadth of neutralizing humoral response to a DNA vaccine targeting the DHBV envelope protein delivered by in vivo electroporation | |
| AU2022366884A1 (en) | Engineering antigen binding to, and orientation on, adjuvants for enhanced humoral responses and immunofocusing | |
| CN1338310A (zh) | 一种猪瘟病毒表位疫苗及其制备方法 | |
| CN119569835A (zh) | 呼吸道合胞病毒f蛋白及其应用 | |
| Iglesias et al. | Coinoculation with hepatitis B surface and core antigen promotes a Th1 immune response to a multiepitopic protein of HIV‐1 | |
| CN115197969A (zh) | 一种治疗乙型肝炎的慢病毒载体、慢病毒颗粒及其制备方法和应用 | |
| RU2006129097A (ru) | Новые тат-комплексы и включающие их вакцины | |
| Rajadhyaksha et al. | Immunological evaluation of three generations of anti-idiotype vaccine: study of B and T cell responses following priming with anti-idiotype, anti-idiotype peptide and its MAP structure | |
| EP0370090B1 (en) | Immunogens and biologically active peptides derived from shared sequences from antigens and anti-idiotypic antibodies or antibodies specific for cellular receptors of the antigens | |
| WO2002032452A1 (en) | Composition for aids and method producing it |